Everolimus is a drug approved for treating neuroendocrine tumors that start in the pancreas (“pancreatic NETs”) after the cancer has progressed despite prior treatment. It works by inhibiting mTOR, a protein involved in cancer growth.
In this study, researchers want to evaluate the safety and effectiveness of everolimus in patients with advanced or inoperable neuroendocrine tumors that began in the lungs or digestive tract (with the exception of pancreatic NETs). Patients will be randomly assigned to receive everolimus or a placebo. All patients will also receive best supportive care.